This is a free sample of content from Synthetic Biology: Tools for Engineering Biological Systems.
Click here for more information on how to buy the book.

Index

A

ADCC. *See* Antibody-dependent cell-mediated cytotoxicity
ADCs. *See* Antibody–drug conjugates
AEGIS. *See* Artificially expanded genetic information systems
Amino acids. *See* Noncanonical amino acids
Antibody-dependent cell-mediated cytotoxicity (ADCC), 220
Antibody–drug conjugates (ADCs), 85–86, 102
AntiSMASH, 186, 188
Artemisinin, 184
Artificially expanded genetic information systems (AEGIS)
  conversion, 64, 67
  laboratory in vitro evolution, 68, 70–72
  large-scale DNA synthesis, 68–69
  nested polymerase chain reaction, 64, 66
  orthogonal AEGIS binding in diagnostics, 59, 61–62
  overview, 56–57, 59
  plasmids in bacterial systems, 72
  polymerase engineering, 62–65
  Z:P pair, 59–60, 68
Automation. *See* Bio-design automation; Electronic design automation

B

Base pairing
  artificial base pairing
    artificially expanded genetic information systems
      conversion, 64, 67
      laboratory in vitro evolution, 68, 70–72
      large-scale DNA synthesis, 68–69
      nested polymerase chain reaction, 64, 66
      orthogonal AEGIS binding in diagnostics, 59, 61–62
      overview, 56–57, 59
      plasmids in bacterial systems, 72
      polymerase engineering, 62–65
      Z:P pair, 59–60, 68
    overview, 55–56
    prospects, 72–73
    ring systems, 58
    rules, 56–57, 59
  Watson–Crick pairing, 52, 54
BDA. *See* Bio-design automation
β islet cell, transplantation, 216
Bio-design automation (BDA)
  data analysis, 155
  data exchange and standardization
    Synthetic Biology Open Language, 158
    Systems Biology Markup Language, 159
  DNA sequence building and editing
    assembly planning, 149, 151–153
    example, 153
    liquid handling, 153
    overview, 147, 149
    vector design, 149–150
  modeling of data, 153–155, 158
  overview, 137–138
  prospects for study, 159–160
  simulations, 154–155, 158
  software tools, 139–144
  specification
    combinatorial specification and design, 146
    example, 147
    rational specification and design, 138, 145
Biodevices, cell-free protein synthesis, 103
Biofilm, formation prevention with phages, 269
Bispecific antibodies, 85–86, 102
Blastocyst complementation, 218

C

CAGE. *See* Conjugative assembly genome engineering
Cancer immunotherapy, cell transplantation, 216
CAR. *See* Chimeric antigen receptor
Carbonic anhydrase, 125
Cell-free protein synthesis (CFPS)
  complex proteins
    assembly, 103–105
    biodevices, 105
    membrane proteins, 103
    therapeutics, 102–103
    vaccines, 103
  genetic networks
    implementation in vitro, 110–111
    overview, 110
    prototyping, 111–113
  noncanonical amino acid incorporation, 106–108
  overview, 95–96
  platforms
    comparison of systems, 99–100
    microbial crude extract systems, 98, 100
    overview, 96–98
    parasitic organ crude extract systems, 101–102
    plant, animal, and insect crude extract systems, 100–101
    PURE systems, 96, 98
  posttranslational incorporation of glycans and metal centers, 108–110
  prospects, 113
CFPS. *See* Cell-free protein synthesis
Chimeric antigen receptor (CAR), 87
Chloroplast, genetic manipulation, 248–250
Circular polymerase extension cloning (CPEC), 14

© 2017 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Synthetic Biology: Tools for Engineering Biological Systems.
Click here for more information on how to buy the book.

Colony self-replication (CSR), polymerase selection for AEGIS, 63–64
Conjugative assembly genome engineering (CAGE), 80
Conversion, AEGIS, 64, 67
CPEC. *See* Circular polymerase extension cloning
CRISPR-Cas9
  gene switch engineering, 200–201
  genome editing, 31–32, 35–37, 40–41
  metabolic engineering, 166
  natural product production strain engineering, 191
  plant applications, 242–243
  transplantation applications, 219
CsoS1, 126
CSR. *See* Colony self-replication
Cytoskeleton, engineering, 129–130

D

Design automation. *See* Bio-design automation; Electronic design automation
DGCL. *See* Diguanylate cyclase
Diguanylate cyclase (DGCL), 200
Dimethyoxytrityl group, phosphoramidite-based oligonucleotide synthesis, 4–5
DNA synthesis
  costs, 3
  error correction and sequence validation, 12–13
  gene synthesis
    microarray-derived oligonucleotide pools, 10–12
    oligonucleotide monomers, 8–10
  long DNA, 13–14
  oligonucleotide synthesis
    column-based synthesis, 4–7
    historical perspective, 4
    microarray-based synthesis, 7–8
  overview, 1–4
  prospects, 14–15

E

EDA. *See* Electronic design automation
Electron paramagnetic resonance (EPR), noncanonical amino acids in proteins, 83
Electronic design automation (EDA), overview, 137
Embryonic stem cell (ESC), transplantation, 216
Encapsulins, protein localization, 127
EPR. *See* Electron paramagnetic resonance
ESC. *See* Embryonic stem cell
Essential gene, 20, 22–24
Extracellular matrix, engineering, 130
FK506-binding protein (FKBP), 122
FKBP. *See* FK506-binding protein

G

Gas vesicles, protein localization, 129
Gene circuit
  biomedical applications, 206–208
  engineering, 203–206
Gene switch
  posttranscriptional gene switches, 201–203
  transcriptional gene switches, 197–201
Gene synthesis. *See* DNA synthesis
Genome editing
  applications
    cell lines and organisms, 37–38
    clinical applications, 38–39
    genome-scale engineering, 38
  CRISPR-Cas9, 31–32, 35–37, 40–41
  homing endonucleases, 31, 37
  overview, 31–33
  prospects, 41
  TALENs, 31–32, 34–35, 41
  targeted transcription factors
    applications, 40–41
    gene expression modulation tools, 39–40
  zinc finger nucleases, 31–34
Glycosylation, cell-free protein synthesis, 108–109
GM-CSF. *See* Granulocyte macrophage colony-stimulating factor
Granulocyte macrophage colony-stimulating factor (GM-CSF), cell-free protein synthesis, 102

H

HDR. *See* Homology-directed repair
Hematopoietic stem cell (HSC), transplantation, 215–216
HIV. *See* Human immunodeficiency virus
Homing endonucleases, genome editing, 31, 37
Homology-directed repair (HDR), genome editing, 32
HSC. *See* Hematopoietic stem cell
Human immunodeficiency virus (HIV), genome editing, 34, 38

I

Induced pluripotent stem cell (iPSC), transplantation, 216
Inverse polymerase chain reaction, 22
iPSC. *See* Induced pluripotent stem cell

J

JCVI-Syn3.0. *See* Minimal cell

K

KRAB–ChaR, 199

L

LSD1, 39
Lumazine synthase, 127–128

M

MAGE. *See* Multiplex automated genome engineering
Magnetosomes, protein localization, 128–129
MamC, 129
Membrane barriers, protein localization, 123–125
Metabolic engineering
  integrated approaches

© 2017 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Synthetic Biology: Tools for Engineering Biological Systems.
Click here for more information on how to buy the book.

overview, 166–167
prospects
enzyme catalysis, 176
production flux optimization, 176
translatome manipulation for enzyme expression, 175–176
limitations, 165–166
plants, 245–246
protein engineering
feedback inhibition reduction, 172–173
overview, 171–172
substrate specificity increase, 173
reactome-level optimization
overview, 174
pathway flux balance, 174–175
transcription and translation engineering
codon optimization, 170–171
overview, 167
reliability of gene expression levels, 167–170
Microcompartments, protein localization, 125–127
Minimal cell
comparative genomics and transposon bombardment of JCVI-Syn3.0 and *Mycoplasma genitalium*, 27
computational models, 27–28
genes
classification by essentiality, 20
JCVI-Syn3.0, 26–27
minimal gene set, computation, 21–22
single-gene inactivation for essential gene determination, 22–24
genome minimization
bottom-up serial deletion, 25–26
top-down serial deletion, 24–25
mycoplasma, 20–21
overview, 19–20
Morphogenesis, synthetic
biomaterial programming, 230–232
overview, 225–226
prospects, 235–236
synthetic life, 232–235
tissue and organ programming, 226–230
Multiplex automated genome engineering (MAGE), 80
Mycoplasma
comparative genomics and transposon bombardment of JCVI-Syn3.0 and *Mycoplasma genitalium*, 27
genome minimization
bottom-up serial deletion, 25–26
top-down serial deletion, 24–25
minimal cell, 20–21
single-gene inactivation for essential gene determination, 22–24

N

Natural product production
design of novel products, 189–191
discovery of natural products, 188–189
diversity of natural products, 186–188
overview, 184–186
production strain engineering, 191
prospects, 191–192
ncAAs. *See* Noncanonical amino acids
Next generation sequencing (NGS), 1–2, 13
NGS. *See* Next generation sequencing
NHEJ. *See* Nonhomologous end joining
Noncanonical amino acids (ncAAs)
applications, 77
cell-free protein synthesis for incorporation, 106–108
genetic encoding, 78, 80–82
mutagenesis, 87–88
orthogonal aminoacyl-tRNA synthetase/tRNA pairs for incorporation, 77, 79
prospects for study, 90
protein engineering with novel properties, 85–88
protein evolution studies, 88–90
spectroscopic probes
protein function, 83–85
protein structure, 82–83
Nonessential gene, 20, 23–24
Nonhomologous end joining (NHEJ), genome editing, 32
Nucleotide base pairing. *See* Base pairing

O

Oligomerized pool engineering (OPEN), 34
Oligonucleotide synthesis. *See* DNA synthesis
Onconase, cell-free protein synthesis, 102
OPEN. *See* Oligomerized pool engineering

P

PCA. *See* Polymerase chain assembly
PCAP. *See* Principal component analysis of proteomics data
PCET. *See* Proton coupled electron transfer
Pdu proteins, 126
Phage therapy
biofilm formation prevention, 269
classical versus synthetic approach, 271
government regulation, 266
host specificity engineering, 262–263
immune response and clearance, 266
infectious disease treatment
administration
inhalation, 268–269
oral, 267
otic, 268
parenteral, 267–268
topical, 268
clinical trials, 269–270
medical device-associated infection, 269
lytic cycle, 262
overview, 261–262
pathogen resistance modulation, 263
pharmacological properties and enhancement, 263–266
production challenges, 266–267
prospects, 272
vaccine applications, 271–272
Phosphoramidite-based synthesis, oligonucleotides, 4–6

© 2017 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Synthetic Biology: Tools for Engineering Biological Systems.
Click here for more information on how to buy the book.

Photocaging, noncanonical amino acids in proteins, 84
PhyB. *See* Phytochrome B
Phytochrome B (PhyB), 199
PIF6, 199
Plants
  chloroplast, genetic manipulation, 248–250
  Marchantia as model chassis, 246–248
  metabolic engineering, 245–246
  multicellular growth models and quantitative microscopy, 250–253
  nuclear transformation, 242–243
  syntax for synthetic genes, 243–244
  synthetic botany
    overview, 241–242
    prospects, 253
  transgene expression control, 243, 245
Polymerase chain assembly (PCA), gene synthesis, 9
Principal component analysis of proteomics data (PCAP), 175
Protein localization, engineering
  encapsulins, 127
  gas vesicles, 129
  lumazine synthase, 127–128
  magnetosomes, 128–129
  membrane barriers, 123–125
  microcompartments, 125–127
  overview, 121–122
  scaffolds, 122–123
  vaults, 128
Proton coupled electron transfer (PCET), noncanonical amino acids in proteins, 83
PURE. *See* Cell-free protein synthesis

Q

Quasi-essential gene, 20, 23

R

RuBisCO, 125–127

S

SBML. *See* Systems Biology Markup Language
SBOL. *See* Synthetic Biology Open Language
Scaffolds, protein localization, 122–123
Small molecule–antibody conjugate, 86–87
Stimulator of interferon genes (STING), 200
STING. *See* Stimulator of interferon genes
Symbiosis, engineering, 130–131
Synthetic Biology Open Language (SBOL), 158
Systems Biology Markup Language (SBML), 159

T

TALENs. *See* Transcription activator-like effector nucleases
TET1, 39
Transcription activator-like effector nucleases (TALENs)
  gene switch engineering, 200–201
  genome editing, 31–32, 34–35, 41
Transplantation, synthetic biology applications
  cells
    β islet cells, 216
    cancer immunotherapy, 216
    embryonic stem cells, 216
    hematopoietic stem cells, 215–216
    induced pluripotent stem cells, 216
  function enhancement, 215
  immunogenicity reduction, 214–215
  organ transplantation
    blastocyst complementation, 218
    decellularization–reecllularization, 217–218
    differentiation, 217
    overview, 216–217
    three-dimensional printing, 217
  overview, 213–214
  prospects, 221–222
  rejection mechanisms
    antibody-dependent cell-mediated cytotoxicity, 220
    coagulation, 221
    control, 215
    donor-specific antibodies, 219
    hematopoietic chimerism, 221
    histocompatibility, 218–219
    inflammation, 220–221
    ischemia/reperfusion injury, 220
    overview, 218
  tolerance induction, 215
Tryptophan synthase, gene circuit engineering, 205

U

Ultraviolet cross-linking, noncanonical amino acids in proteins, 84
URAT1, 207

V

Vaccines
  cell-free protein synthesis, 103
  phage applications, 271–272
Vascular endothelial growth factor (VEGF), phage display, 272
Vaults, protein localization, 128
VEGF. *See* Vascular endothelial growth factor
Vitamin B12, grand challenge synthesis, 52–53

W

Watson–Crick pairing. *See* Base pairing

Z

ZFNs. *See* Zinc finger nucleases
Zinc finger nucleases (ZFNs)
  gene switch engineering, 200–201
  genome editing, 31–34

© 2017 by Cold Spring Harbor Laboratory Press. All rights reserved.